Paradigm Biopharmaceuticals Ltd News

Paradigm Biopharmaceuticals Ltd: Change in substantial holding

May 21 18:24 ET

Paradigm Biopharmaceuticals Ltd: Application for quotation of securities - PAR

May 20 02:03 ET

Paradigm Biopharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Apr 29 19:54 ET

Paradigm Biopharmaceuticals Ltd: Notification of cessation of securities - PAR

Apr 26 02:46 ET

Paradigm Biopharmaceuticals Ltd: Type D Response Submitted and Received by the US FDA

Apr 18 18:36 ET

Paradigm Biopharmaceuticals Ltd: Notification of cessation of securities - PAR

Apr 5 04:49 ET

Paradigm Biopharmaceuticals Ltd: PAR to present at NWR Healthcare Conference

Mar 19 23:45 ET

Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice

Mar 7 21:18 ET

Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice

Mar 7 21:17 ET

Paradigm Biopharmaceuticals Ltd: Final Director's Interest Notice

Mar 5 17:27 ET

Paradigm Biopharmaceuticals Ltd: Initial Director's Interest Notice

Mar 3 19:20 ET

Paradigm Biopharmaceuticals Ltd: Paradigm Board Changes

Mar 3 17:14 ET

Paradigm Biopharmaceuticals Ltd: Notification regarding unquoted securities - PAR

Feb 28 18:22 ET

Paradigm Biopharmaceuticals Ltd: PAR Employee Performance Rights Plan Issue

Feb 28 18:17 ET

Paradigm Biopharmaceuticals Ltd: Half Yearly Report and Accounts

Feb 27 20:15 ET

Paradigm Biopharmaceuticals Ltd: Notification regarding unquoted securities - PAR

Feb 12 21:21 ET

Paradigm Biopharmaceuticals Ltd: Proposed issue of securities - PAR

Feb 11 16:26 ET

Paradigm Biopharmaceuticals Ltd: PAR Appoints Business Development Consultant

Feb 9 00:45 ET

Paradigm Biopharmaceuticals Ltd: Primary Endpoint Achieved in Phase 2 MPS VI Trial

Feb 8 17:04 ET

Paradigm Biopharmaceuticals Ltd: Paradigm Receives $7.36m R&D Tax Incentive Refund

Feb 6 17:14 ET